Exalenz Bioscience Names Ted Foltyn New VP of Worldwide Marketing and Business Development

  Exalenz Bioscience Names Ted Foltyn New VP of Worldwide Marketing and
  Business Development

Business Wire

JERSEY CITY, N.J. -- June 24, 2013

Exalenz Bioscience (TASE: EXEN), developer of the BreathID^®, an advanced
diagnostic system that uses a patient’s breath to quickly and easily identify
and manage specific digestive and liver conditions, announced today that
industry expert Ted Foltyn has joined the company as its new vice president of
worldwide marketing and business development. Today’s news follows the March
2013 appointment of the company’s new CEO Mr. Lawrence Cohen and the May 2013
FDA market clearance of the company’s next generation BreathID technology in
the U.S.

“Exalenz is gearing up for the quickly approaching market launch of the new
generation BreathID Hp. Part of this means expanding our marketing and
business development team. We warmly welcome Ted to the Exalenz family. We are
certain that the company will greatly benefit from his clear vision,
outstanding guidance and many years of industry success,” said Exalenz CEO Mr.
Lawrence Cohen.

Mr. Foltyn is a mentor at the University of Delaware’s National Science
Foundation, Innovation Corps Program and the former senior director of sales
and marketing at Johnson and Johnson, where he managed a $12MM annual budget
and led among other successful initiatives, the commercialization effort for
VERV^®, a first-to-market neuromodulation device. He was honored by the
company with the prestigious OMP OPTIMUS Award for Consistently Outstanding
Leadership. Mr. Foltyn received five J&J Standards of Leadership Awards during
his tenure.

Prior to this, Mr. Foltyn worked for two J&J owned companies. He served as
vice president of worldwide marketing for Ethicon Women’s Health and Urology.
He also held a series of managerial sales and marketing positions at
Ortho-McNeil Pharmaceuticals, the last being director of product development.
Mr. Foltyn earned a B.S. in economics from the University of Delaware and an
MBA in finance from Northeastern University.

“BreathID is truly a remarkable device. It quickly and accurately determines
if a patient has H. pylori, a bacteria that causes various illnesses. As test
results are available almost immediately, physicians are able to promptly
treat patients as well as continuously and easily monitor them for eradication
of the bacteria,” said Mr. Foltyn. “It is with great pleasure that I join
Exalenz. I look forward to working together with the talented and driven team,
under the astute and focused leadership of CEO Mr. Lawrence Cohen. Together we
will creatively drive company growth and increase our presence in the U.S.
using various tools including education.”

About Exalenz Bioscience

Exalenz Bioscience develops medical equipment that uses the breath to diagnose
and help manage digestive system and liver conditions by identifying the
presence of the H. pylori bacteria, the cause of various illnesses. To date,
blood tests or stool samples have been used to detect the same, in
uncomfortable procedures which have limited accuracy and which require days to
secure results. The company’s flagship product, the BreathID, is patient and
technician friendly, provides results in a matter of minutes, and is
clinically proven to be extremely accurate. Unlike the competition, the
BreathID takes continuous samples of breath and operation is as simple as
pushing one button. The BreathID system is FDA cleared and has a CE mark.

For more information: www.exalenz.com
Follow us on Twitter.
Watch our product video.

This news release may contain “forward-looking statements.” Statements in this
press release, which are not purely historical, are forward-looking statements
including statements concerning the Company’s business outlook or future
economic performance, anticipated revenues, expenses or other financial items,
plans and objectives related thereto, and assumptions or expectations relating
to any future events, conditions, performance or other matters.
Forward-looking statements are subject to risks, uncertainties and factors
including, but not limited to, changing customer demands, changing regulatory
requirements, customer acceptance of the Company's products, the impact of
competitive products and pricing, dependence on existing management, that
technology may not function as expected and general economic conditions. The
Company assumes no obligation to update the information in this release.

Contact:

Exalenz Bioscience
Marjie Hadad, +972-54-536-5220
Media Liaison
marjie@netvision.net.il